EngMab

For the development of its T-cell bispecific antibody projects until first clinical proof-of-concept, EngMab closely collaborates with highly experienced research organizations focused on cancer immunotherapy and world-class leading academic and scientific groups specialized in basic science and clinical research in selected hematological malignancies and solid tumors.

Project 1 is a T-cell bispecific antibody for a high unmet medical need hematological malignancy.

Project 2 is a T-cell bispecific antibody targeting a tumor antigen expressed on hematological malignancies and solid tumors.